Abstract: An electric vehicle includes: a side member; and a mechanical-electrical integrated unit attached to the side member through a fastener. The mechanical-electrical integrated unit is constituted by a drive apparatus and an electric-power control apparatus that are housed in a same casing. The casing has an upper space and a lower space that are vertically separated within the casing. The electric-power control apparatus is housed in the upper space while the drive apparatus is housed in the lower space. A plate is provided in the upper space. The side member includes a fragile portion that is located in a position overlapping the plate as viewed in a width direction of the electric vehicle.

Abstract: An electric vehicle includes: a side member; and a mechanical-electrical integrated unit attached to the side member through a fastener. The mechanical-electrical integrated unit is constituted by a drive apparatus and an electric-power control apparatus that are housed in a same casing. The casing has an upper space and a lower space that are vertically separated within the casing. The electric-power control apparatus is housed in the upper space while the drive apparatus is housed in the lower space. The fastener is attached to a fastened portion which is provided in a side wall of the casing and which is thicker than a surrounding portion surrounding the fastened portion. The side member includes a fragile portion that is located in a position overlapping the fastened portion as viewed in a width direction of the vehicle.

Abstract: The object of the present invention is to provide a compound having a treatment effect based on a chemokine inhibitory activity, which is satisfactory as a pharmaceutical product for oral administration. The present inventors have found that the following benzylpiperidine derivative (the formula (1)) has a chemokine inhibitory activity. Further intensive studies have resulted in successful enhancement of the chemokine inhibitory activity and stability in blood of the present compound, as well as the completion of the present invention. wherein each symbol is as defined in the specification.

Abstract: The object of the present invention is to provide a compound having a treatment effect based on a chemokine inhibitory activity, which is satisfactory as a pharmaceutical product for oral administration.

Abstract: The present invention relates to an IgE antibody production inhibitor and an autoimmune disease suppressant containing a heterocyclic amide compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient wherein R represents a hydrogen atom, alkyl, —CHO, —COOH, etc.; R5, R6 and R7 represent each hydrogen, alkyl, aryl, etc.; M represents a carbon atom or a nitrogen atom; Y represents aryl, etc.; and Z represents hydrogen, alkyl, aryl, etc.

Abstract: An agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, an agent for the prophylaxis and treatment of allergic diseases, an agent for the prophylaxis and treatment of eosinophil-related diseases and an eosinophilia inhibitor, comprising, as an active ingredient, a series of triazole derivatives of the following formula (I) ##STR1## or the following formula (III) ##STR2## wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A novel monocyclic or bicyclic triazole derivative. The agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, the agent for the prophylaxis and treatment of allergic diseases, the agent for the prophylaxis and treatment of eosinophil-related diseases, the eosinophilia inhibitor and the novel triazole derivative of the present invention all, have superior eosinophilia-inhibitory action and lymphocyte activation-inhibitory action.

Abstract: Aminophenol derivatives of the following formula (I) ##STR1## wherein X is hydrogen atom, lower alkyl or a protecting group for phenolic hydroxy, Y is hydrogen atom or lower alkyl, Z is hydrogen atom, lower alkyl, halogen atom or trifluoromethyl, A is hydrogen atom or lower alkyl, t is an integer of 1 to 5, l and m are respectively an integer of 2 to 4, E and W are nitrogen atoms, F is a direct bond or oxygen atom, P and Q are each hydrogen atom, halogen atom, lower alkyl or lower alkoxy, and R.sup.8 is hydrogen atom, hydroxy or a hydroxy-protecting group, and their pharmcologically acceptable salts. Since the aminophenol derivatives (I) of the present invention have excellent antioxidative action and antiinflammatory and antiallergic action in mammalian animals including human, they are extremely useful as pharmaceuticals such as an antiinflammatory or an antiallergic.